Brain Delivery Strategies for Biomacromolecular Drugs: Intranasal Administration DOI Creative Commons
Huanhuan Wu, Chenyu Li, Hong Yuan

и другие.

International Journal of Nanomedicine, Год журнала: 2025, Номер Volume 20, С. 6463 - 6487

Опубликована: Май 1, 2025

Macromolecular Drugs (including monoclonal antibodies, recombinant proteins, and nucleic acid therapies) have become a cornerstone strategy for intervening in complex pathological mechanisms such as cancer, autoimmune diseases, genetic disorders due to their high specificity disease targets low off-target toxicity. However, compared traditional small-molecule drugs, the molecular weight (>10 kDa) structural complexity of macromolecular drugs result extremely transmembrane permeability. This is particularly challenging treatment central nervous system (CNS) where blood-brain barrier (BBB) imposes stringent selectivity, further limiting drug delivery efficiency. review focuses on breakthrough nose-to-brain (NtB) delivery. On one hand, NtB pathway bypasses BBB, enabling direct CNS other nanocarrier technology can synergistically achieve systemic brain-targeted transport. Based latest research advances, this article systematically examines feasibility delivering via administration. We comprehensively summarize relevant carriers discuss potential advantages intranasal-brain treatment. Notably, while significant progress has been made field, exploration still needed regarding challenges clinical translation.

Язык: Английский

Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies DOI Creative Commons
Jurga Bernatonienė,

Mindaugas Plieskis,

Kęstutis Petrikonis

и другие.

Pharmaceutics, Год журнала: 2025, Номер 17(3), С. 352 - 352

Опубликована: Март 9, 2025

Pharmaceutical 3D printing, combined with nanomaterials and nanodevices, presents a transformative approach to precision medicine for treating neurological diseases. This technology enables the creation of tailored dosage forms controlled release profiles, enhancing drug delivery across blood−brain barrier (BBB). The integration nanoparticles, such as poly lactic-co-glycolic acid (PLGA), chitosan, metallic nanomaterials, into 3D-printed scaffolds improves treatment efficacy by providing targeted prolonged release. Recent advances have demonstrated potential these systems in conditions like Parkinson’s disease, epilepsy, brain tumors. Moreover, printing allows multi-drug combinations personalized formulations that adapt individual patient needs. Novel approaches, including stimuli-responsive systems, on-demand dosing, theragnostics, provide new possibilities real-time monitoring disorders. Despite innovations, challenges remain terms scalability, regulatory approval, long-term safety. future perspectives this suggest its revolutionize treatments offering patient-specific therapies, improved penetration, enhanced outcomes. review discusses current state, applications, nanotechnology treatment, highlighting need further research overcome existing challenges.

Язык: Английский

Процитировано

0

Dimethyl Fumarate Sterically Stabilized Solid Lipid Nanoparticles. Physicochemical properties and in vitro drug release DOI Open Access

Ferreira da Silva Gisela Bevilacqua Rolfsen,

Daynara D. Souza,

de Souza Moraes Ariana

и другие.

International Journal of Nanomaterials Nanotechnology and Nanomedicine, Год журнала: 2025, Номер 11(1), С. 015 - 026

Опубликована: Янв. 1, 2025

In this work Dimethyl Fumarate (DMF)-loaded and DMF-unloaded Solid Lipid Nanoparticles (SLNs) were developed characterized by Dynamic Light Scattering (DLS), Atomic Force Microscopy (AFM), Scanning Electron (SEM), Differential Calorimetry (DSC), X-ray Diffraction (XRD). vitro release assay was also performed, DMF quantified GC-MS. SLNs prepared a two-step methodology using hot nanoemulsification followed ultrasound irradiation. The results of the mean diameter, polydispersity, zeta potential in range 157 to 525 nm, 0.20 0.6, -30 -7mV, respectively. with spherical elliptical shapes evidenced AFM SEM techniques. XRD DSC analyses revealed strong interaction among SLN components significant loss crystallinity set these structured SLNs. Encapsulation efficiency up 99% loading capacity dependent on O/S ratio has been achieved. could be analyzed first-order kinetics.

Язык: Английский

Процитировано

0

High-cis astaxanthin nano lipid carrier: Preparation and bioavailability analysis DOI

C. Han,

Xintong Zhang, Chenchen Li

и другие.

Food Bioscience, Год журнала: 2025, Номер unknown, С. 106780 - 106780

Опубликована: Май 1, 2025

Язык: Английский

Процитировано

0

Brain Delivery Strategies for Biomacromolecular Drugs: Intranasal Administration DOI Creative Commons
Huanhuan Wu, Chenyu Li, Hong Yuan

и другие.

International Journal of Nanomedicine, Год журнала: 2025, Номер Volume 20, С. 6463 - 6487

Опубликована: Май 1, 2025

Macromolecular Drugs (including monoclonal antibodies, recombinant proteins, and nucleic acid therapies) have become a cornerstone strategy for intervening in complex pathological mechanisms such as cancer, autoimmune diseases, genetic disorders due to their high specificity disease targets low off-target toxicity. However, compared traditional small-molecule drugs, the molecular weight (>10 kDa) structural complexity of macromolecular drugs result extremely transmembrane permeability. This is particularly challenging treatment central nervous system (CNS) where blood-brain barrier (BBB) imposes stringent selectivity, further limiting drug delivery efficiency. review focuses on breakthrough nose-to-brain (NtB) delivery. On one hand, NtB pathway bypasses BBB, enabling direct CNS other nanocarrier technology can synergistically achieve systemic brain-targeted transport. Based latest research advances, this article systematically examines feasibility delivering via administration. We comprehensively summarize relevant carriers discuss potential advantages intranasal-brain treatment. Notably, while significant progress has been made field, exploration still needed regarding challenges clinical translation.

Язык: Английский

Процитировано

0